Clinical Report: Albumin Therapy Tested in Septic Shock

Overview

A multicenter randomized clinical trial conducted in Germany found that albumin replacement therapy did not significantly reduce mortality in patients with septic shock. The study involved 440 adults treated in 23 ICUs between October 2019 and May 2022, comparing albumin therapy to standard fluid management, with no meaningful differences in survival or secondary outcomes.

Background

Septic shock is a critical condition characterized by severe circulatory failure due to an unregulated response to infection, leading to high mortality rates. Albumin has been considered for its potential benefits in maintaining oncotic pressure and its anti-inflammatory properties. Previous studies suggested possible survival benefits, prompting further investigation into its efficacy in septic shock management, including trials that indicated a potential advantage in specific patient populations.

Data Highlights

These rates indicate no significant difference in mortality outcomes between the two groups.

Key Findings

• Albumin therapy did not significantly reduce 90-day mortality compared to standard fluid management.
• Mortality rates were 43% in the albumin group versus 46% in the control group.
• Secondary outcomes, including organ dysfunction and ICU length of stay, were similar between groups.
• Adverse events occurred in 55% of the albumin group and 48% of controls, with no significant differences in types or severity.
• The trial was underpowered due to premature termination, leaving findings inconclusive and necessitating further research.

Clinical Implications

Clinicians should be cautious in using albumin as a routine adjunct therapy for septic shock, as current evidence does not support its efficacy in improving survival. Standard fluid management with crystalloids remains the recommended approach, with albumin reserved for specific clinical scenarios, particularly in subgroups that may benefit.

Conclusion

The trial indicates that while albumin replacement therapy is safe, it does not confer a survival advantage in septic shock. Further research is necessary to explore potential benefits in specific patient subgroups, as the findings remain inconclusive due to the trial's premature termination.

References

1. Albumin Replacement Therapy in Septic Shock: A Randomized Clinical Trial, JAMA Network Open, 2023 -- Albumin Replacement Therapy in Septic Shock: A Randomized Clinical Trial
2. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026, SCCM -- Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026
3. Intensive Care Medicine — Reevaluating the Need for Multiple Clinical Trials in Sepsis Management
4. Intensive Care Medicine — Review of Key Developments in Intensive Care Medicine for 2011: Focus on Cardiovascular Issues, Infections, Pneumonia, Sepsis, Critical Care Organization and Outcomes, Education, Ultrasonography, Metabolism, and Coagulation
5. Critical Care (Springer) — Adjunctive terlipressin versus placebo in the treatment of refractory septic shock: a randomized, placebo-controlled trial
6. conexiant — Emerging Strategies for Septic Shock Management
7. Emerging Strategies for Septic Shock Management
8. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026 | SCCM
9. Albumin Replacement Therapy in Septic Shock: A Randomized Clinical Trial | Critical Care Medicine | JAMA Network Open | JAMA Network
10. Fluid resuscitation management in patients with sepsis and septic shock: a network meta-analysis - PubMed